See more : Scatec ASA (STECF) Income Statement Analysis – Financial Results
Complete financial analysis of Emmaus Life Sciences, Inc. (EMMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emmaus Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cryomass Technologies Inc. (CRYM) Income Statement Analysis – Financial Results
- Chunbo Co., Ltd. (278280.KQ) Income Statement Analysis – Financial Results
- ProKidney Corp. (PROK) Income Statement Analysis – Financial Results
- Global Consumer Acquisition Corp. (GACQ) Income Statement Analysis – Financial Results
- Wearable Devices Ltd. (WLDSW) Income Statement Analysis – Financial Results
Emmaus Life Sciences, Inc. (EMMA)
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.60M | 18.39M | 20.61M | 23.17M | 22.75M | 1.32M | 128.50K | 85.10K | 100.10K | 135.10K | 130.90K | 115.00K | 745.90K | 638.50K | 700.10K | 773.50K | 238.40K | 0.00 | 0.00 | 0.00 | 6.80K | 7.89K | 8.28K | 14.26K | 20.00K |
| Cost of Revenue | 1.34M | 2.59M | 3.31M | 2.25M | 1.09M | 827.40K | 53.50K | 5.50K | 4.90K | 73.00K | 142.60K | 132.00K | 147.10K | 135.10K | 131.60K | 163.20K | 166.20K | 0.00 | 0.00 | 0.00 | 885.00 | 1.21K | 1.15K | 5.78K | 10.00K |
| Gross Profit | 28.26M | 15.80M | 17.30M | 20.92M | 21.66M | 488.10K | 75.00K | 79.60K | 95.20K | 62.10K | -11.70K | -17.00K | 598.80K | 503.40K | 568.50K | 610.30K | 72.20K | 0.00 | 0.00 | 0.00 | 5.91K | 6.68K | 7.13K | 8.48K | 10.00K |
| Gross Profit Ratio | 95.47% | 85.93% | 83.93% | 90.30% | 95.19% | 37.10% | 58.37% | 93.54% | 95.10% | 45.97% | -8.94% | -14.78% | 80.28% | 78.84% | 81.20% | 78.90% | 30.29% | 0.00% | 0.00% | 0.00% | 86.98% | 84.66% | 86.15% | 59.49% | 50.00% |
| Research & Development | 1.19M | 1.73M | 4.11M | 2.41M | 2.18M | 1.38M | 1.36M | 794.20K | 783.80K | 1.45M | 1.29M | 853.70K | 924.80K | 1.12M | 2.14M | 2.10M | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.89M | 13.17M | 13.44M | 13.68M | 17.01M | 7.36M | 4.42M | 2.50M | 1.62M | 2.03M | 2.54M | 2.94M | 4.27M | 5.02M | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.40K | 15.55K | 20.00K |
| Selling & Marketing | 8.64M | 7.49M | 5.88M | 4.87M | 6.98M | 1.99M | 1.40M | 550.50K | 347.90K | 390.20K | 366.30K | 997.10K | 1.23M | 870.90K | 915.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.53M | 20.66M | 19.32M | 18.54M | 23.99M | 9.36M | 5.82M | 3.05M | 1.97M | 2.42M | 2.90M | 3.94M | 5.50M | 5.89M | 4.80M | 3.99M | 1.90M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Other Expenses | 0.00 | -3.98M | 0.00 | 0.00 | -3.34M | 0.00 | 0.00 | 306.70K | 0.00 | 44.10K | 0.00 | 0.00 | 381.70K | 0.00 | 320.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.72M | 22.39M | 23.43M | 20.95M | 26.17M | 10.73M | 7.18M | 3.85M | 2.75M | 3.88M | 4.19M | 4.79M | 6.43M | 7.01M | 6.94M | 6.08M | 3.34M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Cost & Expenses | 26.06M | 24.98M | 26.74M | 23.20M | 27.26M | 11.56M | 7.23M | 3.85M | 2.76M | 3.95M | 4.33M | 4.92M | 6.58M | 7.14M | 7.07M | 6.25M | 3.51M | 416.21K | 28.58K | 261.09K | 145.43K | 18.27K | 17.55K | 21.33K | 30.00K |
| Interest Income | 681.00K | 680.00K | 761.00K | 2.30M | 232.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 0.00 | 0.00 | 99.50K | 104.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 11.00 | 0.00 |
| Interest Expense | 7.38M | 5.01M | 3.10M | 5.99M | 27.39M | 86.30K | 6.60K | 2.72M | 257.40K | 0.00 | 1.29M | 0.00 | 7.57M | 1.67M | 2.14M | 0.00 | 115.60K | 18.53K | 30.57K | 4.51K | 725.00 | 458.00 | 203.00 | 0.00 | -10.00K |
| Depreciation & Amortization | 32.00K | 53.00K | 59.00K | 60.00K | 73.00K | 113.10K | 48.70K | 7.20K | 7.60K | 10.30K | 13.00K | 18.80K | 11.90K | 9.40K | 9.10K | 6.30K | 19.90K | 225.00K | 39.33K | 0.00 | 96.00 | 0.00 | 65.00 | 231.00 | -20.00K |
| EBITDA | 3.57M | -5.50M | -12.76M | 28.00K | -26.98M | -10.13M | -7.05M | -3.19M | -3.12M | -2.63M | -4.19M | -4.79M | -1.29M | -7.80M | -6.67M | -5.47M | -3.25M | 553.80K | -1.09M | -261.09K | -138.63K | -10.38K | -9.20K | -6.84K | -30.00K |
| EBITDA Ratio | 12.07% | -35.81% | -39.02% | 0.07% | -36.01% | -769.82% | -5,490.19% | -4,726.56% | -2,179.42% | -3,654.92% | 875.63% | -4,162.70% | -779.93% | -812.51% | -850.25% | -706.89% | -1,407.97% | 0.00% | 0.00% | 0.00% | -2,041.27% | -131.43% | -111.20% | -47.98% | -150.00% |
| Operating Income | 3.54M | -6.59M | -6.13M | -43.00K | -4.51M | -10.24M | -7.10M | -3.77M | -2.66M | -3.82M | -4.20M | -4.81M | -5.83M | -6.51M | -6.69M | -5.47M | -3.27M | -416.21K | -28.58K | -261.09K | -138.63K | -10.38K | -9.27K | -7.07K | -10.00K |
| Operating Income Ratio | 11.96% | -35.81% | -29.73% | -0.19% | -19.83% | -778.78% | -5,528.09% | -4,426.32% | -2,653.75% | -2,825.17% | -3,209.01% | -4,179.04% | -781.53% | -1,018.79% | -955.88% | -707.71% | -1,371.48% | 0.00% | 0.00% | 0.00% | -2,039.86% | -131.43% | -111.99% | -49.60% | -50.00% |
| Total Other Income/Expenses | -7.33M | -3.98M | -9.79M | 1.01M | -50.17M | -317.80K | -6.60K | -2.17M | -724.60K | 1.16M | -6.69M | 1.89M | -2.50M | -1.67M | -1.82M | 104.00K | -8.70K | -18.53K | 8.76K | -4.51K | -629.00 | -458.00 | -197.00 | 11.00 | -10.00K |
| Income Before Tax | -3.79M | -10.63M | -15.92M | 719.00K | -54.68M | -10.33M | -7.11M | -5.94M | -3.38M | -2.65M | -10.89M | -2.91M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -434.74K | -19.82K | -265.60K | -139.26K | -10.83K | -9.47K | -7.06K | -20.00K |
| Income Before Tax Ratio | -12.81% | -57.78% | -77.25% | 3.10% | -240.32% | -785.34% | -5,533.23% | -6,978.73% | -3,377.62% | -1,965.14% | -8,317.19% | -2,534.26% | -1,188.54% | -1,280.06% | -1,216.25% | -694.26% | -1,375.13% | 0.00% | 0.00% | 0.00% | -2,049.12% | -137.23% | -114.37% | -49.53% | -100.00% |
| Income Tax Expense | -59.00K | 60.00K | 25.00K | -381.00K | 164.00K | 1.90K | 2.60K | 2.00K | 5.00K | 5.20K | 800.00 | 1.90K | 1.30K | 800.00 | 7.20K | 1.40K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 20.00K |
| Net Income | -3.73M | -10.69M | -15.95M | 1.35M | -54.84M | -9.60M | -7.11M | -5.94M | -3.38M | -2.66M | -10.91M | -3.41M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -435.54K | -20.62K | -266.40K | -140.06K | -11.63K | -10.27K | -7.86K | -40.00K |
| Net Income Ratio | -12.61% | -58.10% | -77.37% | 5.84% | -241.04% | -729.66% | -5,535.25% | -6,981.08% | -3,376.02% | -1,970.98% | -8,332.62% | -2,962.43% | -1,188.71% | -1,280.19% | -1,217.28% | -694.44% | -1,375.46% | 0.00% | 0.00% | 0.00% | -2,060.89% | -147.37% | -124.03% | -55.14% | -200.00% |
| EPS | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| EPS Diluted | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| Weighted Avg Shares Out | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.59K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
| Weighted Avg Shares Out (Dil) | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.60K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
Emmaus Life Sciences to focus on boosting sales of its sickle cell disease treatment Endari amid leadership transition
Emmaus Life Sciences Inc (OTCQX:EMMA) said its Dr. Yutaka Niihara will no longer serve as the company's CEO as Dr.
Emmaus Life Sciences Reports Management Changes
Principal Inventor of Endari® (L-glutamine oral powder) and Long-time Chairman and Chief Executive Officer Free to Purse New Projects Company Appoints Interim Co-Presidents to Focus on Core Business TORRANCE, Calif. , Aug. 23, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc....
Emmaus Life Sciences 2Q revenue surges as MENA sales climb
Emmaus Life Sciences Inc (OTCQX:EMMA) has announced record second-quarter 2023 net revenues of $10.8 million, up from $4.3 million a year earlier and its sixth straight quarterly increase, which the company attributed primarily to a $4.1 million increase in net revenues from sales in the...
Emmaus Life Sciences Reports Q2 2023 Financial Results
Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net Revenues TORRANCE, Calif. , Aug. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...
Emmaus Life Sciences receives approval to market Endari in Oman
Emmaus Life Sciences Inc (OTCQX:EMMA) announced that it has received marketing authorization from the Ministry of Health in Oman for the commercial distribution and sale of Endari (L-glutamine oral powder) in the country to treat sickle cell disease in patients...
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman
Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif. , July 13, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing authorization from...
Emmaus Life Sciences receives approval to market Endari in Bahrain
Emmaus Life Sciences Inc (OTCQX:EMMA) announced that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA), granting marketing authorization for the commercial distribution and sale of Endari in the Kingdom of Bahrain. The commercial-stage...
Emmaus Life Sciences sees 1Q revenue surge 109% on boost in US and MENA sales
Emmaus Life Sciences Inc (OTCQX:EMMA) has announced that its first-quarter 2023 net revenues rose 109% year over year to $6.8 million, which the company attributable primarily to higher sales in both the US and the Middle East North Africa (MENA) region. The...
Emmaus Life Sciences sees ‘strong' sales momentum for coming year
Emmaus Life Sciences Inc (OTCQX:EMMA) has said sales momentum is “strong” for the coming year as it reported results the 12 months ended December 31, 2022. In a statement, Dr Yutaka Niihara, chairman and chief executive officer of Emmaus, said: "Despite...
Emmaus Life Sciences CEO Dr Yutaka Niihara highly praised by the Indian government for developing Endari
Emmaus Life Sciences Inc (OTCQX:EMMA) revealed that the company's CEO Dr Yutaka Niihara was feted at an event held on December 16, 2022, at the World Trade Center in Mumbai, India, by Indian Minister of State Arun Halder, in recognition...
Source: https://incomestatements.info
Category: Stock Reports